Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a report issued on Monday,Benzinga reports. They presently have a $18.00 price objective on the stock. D. Boral Capital’s price objective indicates a potential upside of 209.70% from the company’s current price.

Several other brokerages have also recently commented on COYA. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, August 25th. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Wednesday, September 17th. Finally, Lake Street Capital initiated coverage on Coya Therapeutics in a report on Wednesday, July 9th. They set a “buy” rating and a $16.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $16.50.

Coya Therapeutics Stock Up 5.9%

COYA opened at $5.81 on Monday. The business has a 50 day moving average price of $6.14 and a two-hundred day moving average price of $5.99. The company has a market cap of $97.23 million, a PE ratio of -4.71 and a beta of 0.26. Coya Therapeutics has a 52 week low of $4.65 and a 52 week high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The business had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.78 million. As a group, sell-side analysts expect that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. acquired a new stake in shares of Coya Therapeutics during the first quarter worth $65,000. Jane Street Group LLC acquired a new stake in shares of Coya Therapeutics during the fourth quarter worth $74,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Coya Therapeutics during the second quarter worth $119,000. Northern Trust Corp boosted its holdings in shares of Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after purchasing an additional 3,099 shares during the last quarter. Finally, Dauntless Investment Group LLC acquired a new stake in shares of Coya Therapeutics during the first quarter worth $1,083,000. 39.75% of the stock is owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.